# SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma

> **NCT06384482** · PHASE1 · UNKNOWN · sponsor: **Shanghai Simnova Biotechnology Co.,Ltd.** · enrollment: 35 (estimated)

## Conditions studied

- Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma

## Interventions

- **DRUG:** SNC115 injection

## Key facts

- **NCT ID:** NCT06384482
- **Lead sponsor:** Shanghai Simnova Biotechnology Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-30
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06384482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06384482, "SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06384482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*